Extended Data Fig. 1: Study outline and clinical outcome of patients. | Nature Immunology

Extended Data Fig. 1: Study outline and clinical outcome of patients.

From: Efficacy of CTLA-4 checkpoint therapy is dependent on IL-21 signaling to mediate cytotoxic reprogramming of PD-1+CD8+ T cells

Extended Data Fig. 1

(A) Schematic of major samples and experimental techniques used in the study. (B) Tumor response of patients evaluated after 3 months. CR: Complete response; PR: partial response; SD: stable disease; PD: progressive disease. In adjuvant group, patients were evaluated either as CR or PD. (C) Kaplan-Meier progression-free survival analysis of patients stratified by therapy regimens (P = 0.045). Statistical significance was determined by Two-sided Log-rank test in (C) (* P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001). Illustrations in A were created using BioRender.com.

Back to article page